3D Printed Absorber for Capturing Chemotherapy Drugs before They Spread through the Body.
Journal
ACS central science
ISSN: 2374-7943
Titre abrégé: ACS Cent Sci
Pays: United States
ID NLM: 101660035
Informations de publication
Date de publication:
27 Mar 2019
27 Mar 2019
Historique:
received:
01
10
2018
entrez:
3
4
2019
pubmed:
3
4
2019
medline:
3
4
2019
Statut:
ppublish
Résumé
Despite efforts to develop increasingly targeted and personalized cancer therapeutics, dosing of drugs in cancer chemotherapy is limited by systemic toxic side effects. We have designed, built, and deployed porous absorbers for capturing chemotherapy drugs from the bloodstream after these drugs have had their effect on a tumor, but before they are released into the body where they can cause hazardous side effects. The support structure of the absorbers was built using 3D printing technology. This structure was coated with a nanostructured block copolymer with outer blocks that anchor the polymer chains to the 3D printed support structure and a middle block that has an affinity for the drug. The middle block is polystyrenesulfonate which binds to doxorubicin, a widely used and effective chemotherapy drug with significant toxic side effects. The absorbers are designed for deployment during chemotherapy using minimally invasive image-guided endovascular surgical procedures. We show that the introduction of the absorbers into the blood of swine models enables the capture of 64 ± 6% of the administered drug (doxorubicin) without any immediate adverse effects. Problems related to blood clots, vein wall dissection, and other biocompatibility issues were not observed. This development represents a significant step forward in minimizing toxic side effects of chemotherapy.
Identifiants
pubmed: 30937369
doi: 10.1021/acscentsci.8b00700
pmc: PMC6439445
doi:
Types de publication
Journal Article
Langues
eng
Pagination
419-427Subventions
Organisme : NCI NIH HHS
ID : R01 CA194533
Pays : United States
Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
The authors declare the following competing financial interest(s): J.M.D. is the co-founder/CEO of and has an equity stake in Carbon, Inc., a 3D printing company commercializing continuous liquid interface production (CLIP) technology. G.R.R. is an employee, and F.M.B. is a former employee of Carbon, Inc. Carbon, Inc. is the manufacturer of CLIP equipment. CLIP is protected under issued US patents including 9,205,601, 9,211,678, and 9,216,546. S.W.H. and M.W.W. are the co-inventors of an in vivo positionable filtration device and methods related thereto to enable chemotherapy delivery in a targeted manner (WO/2014/100201).
Références
J Vasc Interv Radiol. 2010 Feb;21(2):259-67
pubmed: 20123210
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Med Device. 2014 Dec;8(4):0410081-410088
pubmed: 25653735
Adv Drug Deliv Rev. 2002 Jan 17;54(1):13-36
pubmed: 11755704
J Synchrotron Radiat. 2018 Jul 1;25(Pt 4):1261-1270
pubmed: 29979189
Biomed Microdevices. 2016 Dec;18(6):98
pubmed: 27778226
Eur J Pharm Sci. 2016 Oct 10;93:351-9
pubmed: 27523788
Hepatogastroenterology. 1998 Nov-Dec;45(24):1961-5
pubmed: 9951848
Biomaterials. 2003 Nov;24(24):4337-51
pubmed: 12922147
Biomed Opt Express. 2016 May 25;7(6):2400-6
pubmed: 27375954
J Pharm Sci. 2007 May;96(5):1320-30
pubmed: 17455363
J Vasc Interv Radiol. 2016 Mar;27(3):426-32.e1
pubmed: 26706187
J Synchrotron Radiat. 2014 Sep;21(Pt 5):1188-93
pubmed: 25178011
Int J Clin Oncol. 2002 Apr;7(2):82-90
pubmed: 12018114
Eur Radiol. 2010 Jan;20(1):173-80
pubmed: 19657653
J Oncol Pharm Pract. 2013 Mar;19(1):65-74
pubmed: 22801955
J Control Release. 1999 Nov 1;62(1-2):81-7
pubmed: 10518639
Biomed Microdevices. 2016 Dec;18(6):109
pubmed: 27830455
Oncologist. 2003;8(5):425-37
pubmed: 14530495
Eur Radiol. 2003 Jan;13(1):136-40
pubmed: 12541121
Langmuir. 2001 Sep 4;17(18):5440-7
pubmed: 12448421
Cancer Chemother Rep. 1970 Dec;54(6):431-50
pubmed: 5527023
Ann Surg. 1998 Apr;227(4):519-26
pubmed: 9563540
J Vasc Interv Radiol. 2011 Nov;22(11):1545-52
pubmed: 21849247
J Natl Cancer Inst. 1987 Aug;79(2):213-6
pubmed: 3474453
NCHS Data Brief. 2017 Dec;(293):1-8
pubmed: 29319473
Radiology. 2008 Oct;249(1):346-54
pubmed: 18796686
ACS Macro Lett. 2016 Aug 16;5(8):936-941
pubmed: 27547493
Oncol Res. 1999;11(11-12):529-37
pubmed: 10905565
Recent Results Cancer Res. 1998;147:67-82
pubmed: 9670270
Radiology. 2009 Jan;250(1):281-9
pubmed: 19092099
Biomaterials. 2010 Jun;31(17):4639-56
pubmed: 20303169
J Mater Sci Mater Med. 2008 Feb;19(2):767-75
pubmed: 17653626
Biomaterials. 1990 Mar;11(2):119-21
pubmed: 2317533
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Surg Oncol. 1995 Aug;4(4):205-16
pubmed: 8528483
J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):335-42
pubmed: 16517780
J Clin Oncol. 1994 Dec;12(12):2723-36
pubmed: 7989950
Ann Surg Oncol. 1994 Sep;1(5):389-99
pubmed: 7850540
Acta Biomater. 2012 May;8(5):1838-48
pubmed: 22285429
Biomed Eng Online. 2015 Jun 30;14:63
pubmed: 26123131
Science. 2015 Mar 20;347(6228):1349-52
pubmed: 25780246
Br J Cancer. 2001 Aug 17;85(4):484-9
pubmed: 11506483